Deutsche Bank AG Raises Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Deutsche Bank AG raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 93.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,441 shares of the company's stock after purchasing an additional 74,275 shares during the period. Deutsche Bank AG owned 0.40% of Tarsus Pharmaceuticals worth $8,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $25,000. R Squared Ltd purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $53,000. Quarry LP purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $166,000. HighTower Advisors LLC purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $207,000. Finally, Summit Investment Advisors Inc. grew its stake in shares of Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after buying an additional 244 shares during the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 2,315 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the sale, the insider now owns 50,751 shares of the company's stock, valued at $2,349,263.79. This trade represents a 4.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Bryan Wahl sold 3,341 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. The trade was a 5.44% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is currently owned by corporate insiders.

Tarsus Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ:TARS opened at $43.70 on Friday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The stock has a market cap of $1.84 billion, a P/E ratio of -11.47 and a beta of 0.94. The business's 50 day moving average is $48.05 and its 200 day moving average is $49.17. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Guggenheim upped their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Jefferies Financial Group upped their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $66.33.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.